insights_auto
Why is DMN up 3,75%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
0,072 €
arrow_upward
+3,75%(+0,0026) 1D
10 նոյ, 15:37:31 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
147,54 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
147,54 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
markets.businessinsider.com
·
5 րոպե առաջ
Dow and ISN® Celebrate More Than 20 Years of Advancing Contractor Safety and Compliance
Yahoo Finance
·
30 րոպե առաջ
SK hynix (NasdaqGS:SKHY) Stock Looks Cheap Following A 20% Slide
The Lufkin Daily News
·
19 րոպե առաջ
Wall St falls as hot inflation data fuels rate-hike jitters
Seeking Alpha
·
26 րոպե առաջ
U.S. equities drift lower after a hotter CPI print
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB